Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
作者： Holmlund Jt , Monia Bp , Dorr Fa , Kwoh Tj
DOI:
关键词: Cancer research 、 Clinical trial 、 Cancer 、 Antisense Oligonucleotide Therapy 、 High selectivity 、 Molecular biology 、 Medicine 、 In vivo 、 Antisense oligonucleotides
摘要: Antisense oligonucleotides offer the promise of therapeutic effect with few toxic effects, by virtue their high selectivity. Preclinical studies have provided evidence antisense effects in vitro and vivo, phase I clinical trials demonstrated safety, feasibility activity for treatment cancer. This review summarizes status development three anticancer from ISIS Pharmaceuticals.
参考文章(0)